018763161

OSYN-C

---

September 15, 2022

Trademark Summary

The trademark application OSYN-C was filed by CarryGenes Therapeutics AB, a corporation established under the laws of the Kingdom of Sweden (the "Applicant"). The application was published for oppositions on May 23, 2023, and it was registered by office on August 30, 2023 without any oppositions.

The application was filed in Swedish (English was selected as the second language).

---

Goods And Services

• The mark was filed in class 1 with following description of goods:
  
  1. Biological and chemical products for use in the pharmaceutical industry and research
  2. Chemical reagents for the manufacture of therapeutic immunotherapy solutions
  3. Cells for scientific or laboratory research.
• The mark was filed in class 5 with following description of goods:
  
  1. Pharmaceutical products
  2. Biological and pharmaceutical preparations
  3. Biological and pharmaceutical preparations for treating cancer and tumors using immunotherapy
  4. T-cells
  5. Biological materials, preparations, reagents for medical products
  6. Antigens, antibodies, cells for therapeutic use
  7. Gene therapy products, namely, genetically engineered cells
  8. Synthetically manufactured chromosomes
  9. Cells for medical research
  10. Chimeric antigen receptor.
• The mark was filed in class 40 with following description of goods:
  
  1. Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy
  2. Manufacturing antigens, antibodies, T-cells
  3. Manufacturing antigen receptors
  4. Manufacturing synthetic chromosomes.
• The mark was filed in class 42 with following description of goods:
  
  1. Scientific research services for medical purposes
  2. Identifying, screening and developing antigens, hereunder chimeric antigen receptor therapy
  3. Scientific and technological services
  4. Scientific laboratory services
  5. Providing scientific and medical information on immunotherapy
  6. Providing services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform
  7. Epigenetic antigen screening and identification services for therapeutic research purposes
  8. Genomic and epigenetic characterization services for identifying drug candidates in immunotherapy
  9. Designing algorithms and models for use in scientific and medical research
  10. Computer software platforms enabling the use of algorithms for analyzing cells, antigens, tissue, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses
  11. Computer software platforms enabling the use of algorithms for forecasting the characteristics of antigens and immunological responses.
• The mark was filed in class 44 with Providing information in the field of manufacturing pharmaceuticals and providing medical information relating to immunotherapy..